Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Forma Therapeutics has entered into a research and development collaboration with Boehringer Ingelheim for the discovery and development of novel drug candidates to treat cancer.
Subscribe to our email newsletter
Both the companies intend to lay emphasis on discovering small molecule drugs against oncology-relevant protein-protein interactions.
As per the deal, Forma will receive a total of $65m in up-front payments and research funding to screen for and optimize compounds against multiple oncology targets over the upcoming four years.
Furthermore, Forma may be entitled to receive up to $750m in pre-commercial milestones for programs resulting from the collaboration.
Forma Research and Development head and senior vice president Kenneth Bair said many un-druggable and/or novel targets in oncology involve protein-protein interactions.
"We are really excited about tackling these essential targets with Boehringer Ingelheim," Bair added.